MECHANISM OF TRH EFFECTS IN FETAL LUNG DEVELOPMENT
MECHANISM OF TRH EFFECTS IN FETAL LUNG DEVELOPMENT
批准号:
2029195
负责人:
UDAY P DEVASKAR
金额:
$15.6万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-12-12 至 1999-11-30
关键词:
adrenal medulla bronchopulmonary dysplasia corticosteroids embryo /fetus enzyme activity epinephrine growth /development hormone regulation /control mechanism laboratory mouse lung neural transmission northern blottings ornithine decarboxylase phosphatidylcholines pituitary thyroid axis protein biosynthesis radioimmunoassay respiratory distress syndrome of newborn statistics /biometry thyrotropin releasing hormone western blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
HMD and BPD remain the major causes of neonatal mortality and norbidity.
Maternal Thyrotropin Releasing Hormone (TRH) treatment enhances fetal
lung maturation, but inhibits antioxidant enzyme (AOE). Nevertheless,
there is an increasing use of prenatal TRH=corticosteroids (CS) for the
prevention of HMD & BPD. The mechanism of TRH effects on fetal lung are
unclear, it may be due to its neuroendocrine or neurotransmitter
actions. To investigate these possibilities, we will use the HYT/HYT
mouse where primary hypothyroidism occurs due to a mutation
(ProyieldsLeu,a.a.556) in the TM4 domain of the beta subunit of the TSH
receptor, & is transmitted as an autosomal recessive trait. We will
test alternative hypotheses that TRH mediates its effect through 1 of 3
pathways: 1) Fetal pituitary-thyroid (TH), 2) Fetal CNS autonomic
sympathetic or parasympathetic neurotransmission, or 3) Fetal adrenal
medullary release of Epinephrine (beta-a drenergic effect). We will
perform fetal lung ultrastructural analysis, quantitate disaturated
phosphatidylcholine (DSPC), the rate of 3H-choline incorporation into
phosphatidaylcholine (PC) & DSPC, & AOE activity, as indices of TRH
effects. Clinically TRH is used with CS, & TRH=CS therapy increases
fetal ling SP-A in animals. We have observed altered protein (SP-A & C)
& gene expression (SP-C) in HYT/HYT mouse fetal lungs. We will study
the effect of prenatal CS, TRH or CS+TRH on fetal lung SP-A & SP-C mRNA
(Northern) & protein expression (Western & immunostaining), along with
other indices of TRH effects. Plasma TSH & free T4 levels (RIA) will
determine the TH status of the Mice. The role of each pathway will be
determined as follows: 1) Pituitary-thyroid-lung axis: Comparison of the
effect on the fetal lung of maternal TRH treatment in the HYT/HYT &
Balb-C mouse; presence of TRH effects in Balb-C & their absence in the
HYT/HYT mouse will indicate a role for the pituitary-thyroid axis. 2)
CNS sympathetic or adrenal medullary Epinephrine (beta adrenergic)
stimulation: Comparison of the effect in the fetal lung of maternal TRH
therapy in the HYT/HYT mouse with & without prior treatment with 6-
hydroxydopamine (6-OHDA, chemical sympathectomy) or Propranolol (beta-
adrenergic blockade) respectively: Absence of TRH effects on the lung in
6-OHDA or Propranolol treated fetuses will suggest a role for the Cnz
sympathetic or beta-adrenergic system respectively. 3) CNS
parasympathetic stimulation: Comparison of the effect on fetal lung of
maternal TRH treatment in the HYT/HYT & Balb-C mouse with & without
prior atropine treatment for cholinergic blockade: A lack of TRH effect
on lungs of Atropine treated fetuses will indicate a role for the
cholinergic system. TRH (24mug/dose) will administered (IP, d16 & 17,
b.i.d.) & 18 (1 h prior to killing) of pregnancy. The vehicle, 6-OHDA,
Propranolol or Atropine will be infused by Alzet pumps starting on d 14.
For TRH+CS studies, vehicle+saline, TRH (24mug/dose) in saline+vehicle,
TRH+Beta. (0.6 mg/dose), or saline+Beta. will be injected on d 16 & 17
(b.i.d.) & 18 of pregnancy. All pregnant mice will be killed on d 18,
(term about 20 d). These studies will further establish the efficacy, &
clarify the mechanism of TRH & TRH+CS~s effect on the fetal lung, & may
provide clues for the prevention of AOE inhibition after TRH treatment &
improved management of neonates prenatally treated with CS+TRH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NICHD Cooperative Multicenter Neonatal Research Network
-
批准号:9257434
-
项目类别:
-
资助金额:$0.77万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network - UCLA
-
批准号:8643284
-
项目类别:
-
资助金额:$29.49万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network
-
批准号:9079306
-
项目类别:
-
资助金额:$0.77万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network - UCLA
-
批准号:8250383
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network - UCLA
-
批准号:8865652
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network - UCLA
-
批准号:8450729
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
NICHD Cooperative Multicenter Neonatal Research Network - UCLA
-
批准号:8081377
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2011
-
负责人:UDAY P DEVASKAR
-
依托单位:
TRGR (TRIAL TO REDUCE INSULIN DIABETES MELLITUS (IDDM) IN THE GENETICALLY AT
-
批准号:7205392
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2004
-
负责人:UDAY P DEVASKAR
-
依托单位:
TRGR (Trial to Reduce Insulin Diabetes Mellitus (IDDM) in the Genetically at...
-
批准号:7043129
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2003
-
负责人:UDAY P DEVASKAR
-
依托单位:
MECHANISM OF TRH EFFECTS IN FETAL LUNG DEVELOPMENT
-
批准号:2609335
-
项目类别:
-
资助金额:$15.81万
-
财政年份:1996
-
负责人:UDAY P DEVASKAR
-
依托单位:
MECHANISM OF TRH EFFECTS IN FETAL LUNG DEVELOPMENT
-
批准号:6021572
-
项目类别:
-
资助金额:$15.03万
-
财政年份:1996
-
负责人:UDAY P DEVASKAR
-
依托单位:
MECHANISM OF TRH EFFECTS IN FETAL LUNG DEVELOPMENT
-
批准号:2839001
-
项目类别:
-
资助金额:$1.0万
-
财政年份:1996
-
负责人:UDAY P DEVASKAR
-
依托单位:
海外基金